Comparative Pharmacology
Head-to-head clinical analysis: ALOMIDE versus CALOMIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOMIDE versus CALOMIST.
ALOMIDE vs CALOMIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lodoxamide stabilizes mast cells by preventing antigen-induced release of histamine and other inflammatory mediators (e.g., SRS-A) from the mast cell, possibly by inhibiting calcium influx.
Calomist (calcium gluconate) provides calcium ions to stabilize cardiac cell membranes, correct hypocalcemia, and antagonize hyperkalemia-induced cardiotoxicity.
1 to 2 drops in each affected eye four times daily (every 6 hours).
Mist inhalation: 1-2 actuations (100-200 mcg) delivered orally via nebulizer every 6 hours as needed for bronchospasm; maximum 12 actuations per day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours. Clinically, this short half-life supports frequent dosing for sustained ocular effects.
Terminal elimination half-life: 4-6 hours; prolonged in renal impairment (up to 20 hours in anuria)
Primarily renal excretion; approximately 50-60% of the dose is excreted unchanged in urine within 24 hours. Fecal elimination accounts for less than 10%. Minor biliary excretion.
Renal: 90% unchanged; biliary/fecal: 10%
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer